Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME ® trial

Open access

Abstract

AIMS: We previously reported that in the EMPA-REG OUTCOME(®) trial, empagliflozin added to standard of care reduced the risk of 3-point major adverse cardiovascular events, cardiovascular and all-cause death, and hospitalization for heart failure in patients with type 2 diabetes and high cardiovascular risk. We have now further investigated heart failure outcomes in all patients and in subgroups, including patients with or without baseline heart failure. METHODS AND RESULTS: Patients were randomized to receive empagliflozin 10 mg, empagliflozin 25 mg, or placebo. Seven thousand and twenty patients were treated; 706 (10.1%) had heart failure at baseline. Heart failure hospitalization or cardiovascular death occurred in a significantly lower percentage of patients treated with empagliflozin [265/4687 patients (5.7%)] than with placebo [198/2333 patients (8.5%)] [hazard ratio, HR: 0.66 (95% confidence interval: 0.55-0.79); P < 0.001], corresponding to a number needed to treat to prevent one heart failure hospitalization or cardiovascular death of 35 over 3 years. Consistent effects of empagliflozin were observed across subgroups defined by baseline characteristics, including patients with vs. without heart failure, and across categories of medications to treat diabetes and/or heart failure. Empagliflozin improved other heart failure outcomes, including hospitalization for or death from heart failure [2.8 vs. 4.5%; HR: 0.61 (0.47-0.79); P < 0.001] and was associated with a reduction in all-cause hospitalization [36.8 vs. 39.6%; HR: 0.89 (0.82-0.96); P = 0.003]. Serious adverse events and adverse events leading to discontinuation were reported by a higher proportion of patients with vs. without heart failure at baseline in both treatment groups, but were no more common with empagliflozin than with placebo. CONCLUSION: In patients with type 2 diabetes and high cardiovascular risk, empagliflozin reduced heart failure hospitalization and cardiovascular death, with a consistent benefit in patients with and without baseline heart failure.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehv728

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 (A) Time to first hospitalization for heart failure or cardiovascular death. (B) Time to first all-cause hospitalization. Cumulative incidence function. Patients treated with at least one dose of study drug. HR, hazard ratio; CI, confidence interval.
Figure 1 (A) Time to first hospitalization for heart failure or cardiovascular death. (B) Time to first all-cause hospitalization. Cumulative incidence function. Patients treated with at least one dose of study drug. HR, hazard ratio; CI, confidence interval.CC BY-NC · PubMed Central
Figure 2 Subgroup analyses of heart failure hospitalization or cardiovascular death and hospitalization for heart failure by baseline characteristics. Patients treated with at least one dose of study drug. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CI, confidence interval; DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; HR, hazard ratio; SBP, systolic blood pressure.
Figure 2 Subgroup analyses of heart failure hospitalization or cardiovascular death and hospitalization for heart failure by baseline characteristics. Patients treated with at least one dose of study drug. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CI, confidence interval; DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; HR, hazard ratio; SBP, systolic blood pressure.CC BY-NC · PubMed Central
Figure 3 Outcomes in patients with and without heart failure at baseline. Cox regression analysis. Patients treated with at least one dose of study drug. CI, confidence interval; HR, hazard ratio.
Figure 3 Outcomes in patients with and without heart failure at baseline. Cox regression analysis. Patients treated with at least one dose of study drug. CI, confidence interval; HR, hazard ratio.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Research works printed but not linked: 1

  1. Jordan, 2014, Empagliflozin has no discernible effect on muscle sympathetic nerve activity in patients with type 2 diabetes despite reductions in blood pressure and weight, Diabetes, 63, A265

Cited by

See all 947

Metadata

Authors
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E.
Affiliations
  • St. Michael's Hospital (CA)
  • Mount Sinai Hospital (CA)
  • University of Würzburg (DE)
  • George Washington University (US)
  • Boehringer Ingelheim (Germany) (DE)
  • Boehringer Ingelheim (United States) (US)
  • Boehringer Ingelheim (Norway) (NO)
  • Yale University (US)
Corresponding author
Fitchett, David
Venue
European Heart Journal
Published
2016-01-26
Volume
37
Issue
19
Pages
1526-1534
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2273304042
Cited by
907
References
29
Citations by year
2026: 18 · 2025: 30 · 2024: 32 · 2023: 55 · 2022: 75 · 2021: 115 · 2020: 102 · 2019: 142 · 2018: 124 · 2017: 131 · 2016: 81
FWCI
160.00
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • European Heart Journal (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Lirias (KU Leuven) (submittedVersion, other-oa)
  • Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nc)
  • Hispana (submittedVersion, cc-by-nc)
  • HighWire Press Open Archive (submittedVersion)
  • Online Publication Service of Würzburg University (Würzburg University) (submittedVersion, cc-by-nc)
Funders
Boehringer Ingelheim and Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
empagliflozin, type 2 diabetes, heart failure hospitalization, cardiovascular mortality, SGLT2 inhibitors, EMPA-REG OUTCOME trial, high cardiovascular risk, all-cause hospitalization, serious adverse events, subgroup analysis, number needed to treat, cardiovascular risk reduction, heart failure treatment, drug discontinuation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME ® trial. https://app.cochat.ai/papers/10.1093/eurheartj/ehv728
The paper
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016). Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME ® trial. European Heart Journal. https://doi.org/10.1093/eurheartj/ehv728

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.